Repeated-dose skin irritation testing is a core safety evaluation that determines whether a cosmetic product or ingredient causes reversible inflammatory reactions after repeated skin contact over time. This technical article explains the test principle, applicable standards such as the Safety and Technical Standards for Cosmetics (2015) and OECD Test Guidelines, sample requirements, methodology, and regulatory applications for manufacturers and formulators worldwide.
Technical Overview
Repeated-dose skin irritation testing, also known as multiple-dose or cumulative skin irritation testing, evaluates whether a cosmetic product or ingredient provokes reversible inflammatory responses in the skin following repeated, prolonged contact. Unlike acute irritation studies, which assess the effects of a single exposure, repeated-dose protocols simulate real-world usage conditions, such as applying a cream or cleanser every day for two consecutive weeks, and therefore provide a more realistic picture of cumulative skin compatibility.
The classical in vivo method is based on the Draize scoring system, in which the test substance is applied to the intact skin of rabbits under a semi-occlusive patch for consecutive days. Trained evaluators grade erythema, eschar formation, and edema on standardized scales, and the results are expressed as a cumulative irritation index. Key regulatory references include the Safety and Technical Standards for Cosmetics (2015) issued by China's National Medical Products Administration, OECD Test Guideline 404 for acute dermal irritation and corrosion, OECD Test Guideline 410 for repeated-dose dermal toxicity, and, for in vitro alternatives, OECD Test Guidelines 431 and 439. Accredited third-party laboratories routinely conduct these studies to support product registration, filing, and safety dossiers.
With the growing adoption of animal testing restrictions, including the marketing ban in the European Union under Regulation (EC) No 1223/2009, reconstructed human epidermis (RhE) in vitro methods and controlled human patch studies have become increasingly important complements or substitutes for the rabbit model.
Testing Samples
Finished Cosmetic Products
Both leave-on products, such as emulsions, creams, lotions, essences, makeup, and sunscreens, and wash-off products, such as shampoos, shower gels, facial cleansers, and hand soaps, can be evaluated. For wash-off products, exposure duration and dilution ratios are adjusted to reflect actual use. Strongly acidic or alkaline formulations, typically with a pH of 2.0 or below or 11.5 or above, may be excluded from testing on corrosivity grounds and assessed through a pH-based waiver.
Raw Materials and New Cosmetic Ingredients
Individual ingredients, including surfactants, preservatives, plant extracts, colorants, and fragrance compounds, are frequently tested to build ingredient safety profiles and to support new cosmetic ingredient registration dossiers. Testing at both the intended use concentration and the neat level provides insight into formulation margins of safety.
Sample Preparation and Vehicle Selection
Solid samples may be moistened with water or another appropriate vehicle, while liquids are generally applied undiluted. The patch system, application amount, commonly 0.5 g or 0.5 mL per site, and exposure time, typically 4 hours per application under semi-occlusion, are documented in the study protocol. Sufficient sample quantity, usually a minimum of 30 to 50 g or mL, is required for a full 14-day repeated-dose study.
Testing Items
The repeated-dose skin irritation test generates the following key observations and calculated endpoints:
- Daily Draize scores for erythema and eschar formation on a 0 to 4 scale at each application site
- Daily Draize scores for edema on a 0 to 4 scale
- Cumulative irritation index calculated from the sum of daily scores across animals and observation days
- Time to onset of irritation and evidence of progressive response with repeated applications
- Reversibility of reactions, assessed through post-exposure observation of up to 14 days
- Additional local effects such as dryness, scaling, fissuring, or staining of the skin
- General clinical observations, body weight records, and any systemic signs noted during the study
Testing Methods
In Vivo Repeated-Dose Dermal Irritation Test
The reference protocol follows the Safety and Technical Standards for Cosmetics (2015) and the general principles of relevant OECD Test Guidelines. Healthy adult rabbits, typically albino, are acclimatized, and the dorsal skin is clipped free of fur shortly before dosing. The test substance is applied to intact skin sites under gauze patches and semi-occlusive coverings for approximately 4 hours per day over 14 consecutive days, with a concurrent negative-control site treated with the vehicle or deionized water. After each patch removal, the skin is wiped clean and evaluated by trained assessors.
- Scoring uses the Draize scale: erythema and eschar from 0, no reaction, to 4, severe erythema to slight eschar formation; edema from 0, no reaction, to 4, severe edema extending beyond the exposure area
- Scores are recorded at approximately 1 hour after patch removal, with additional readings at 24 hours or later depending on the protocol
- The cumulative irritation index is computed as the total score divided by the number of applications, animals, and readings
- If severe reactions develop, dosing at that site is discontinued and the recovery process is monitored and documented
In Vitro Reconstructed Human Epidermis Methods
For corrosivity and acute irritation assessment, OECD Test Guideline 431 and OECD Test Guideline 439 define validated in vitro tests using reconstructed human epidermis models. The test material is applied topically to a three-dimensional human epidermis construct, and cytotoxicity, usually quantified through MTT reduction, after a defined exposure and post-incubation period is used to predict irritation potential. These methods are accepted in many jurisdictions as stand-alone replacements for the rabbit acute irritation test and, when combined with other data in a weight-of-evidence approach, can reduce or avoid animal testing for repeated-exposure safety evaluations.
Human Cumulative Irritation Patch Testing
Under independent ethical review and informed consent, controlled human patch studies, such as 21-day cumulative irritation assays, apply the product to panelist skin under occlusion and grade responses through dermatological assessment. These studies are valuable for safety substantiation and for supporting claims such as suitability for sensitive skin or dermatologically tested, although they do not replace regulatory toxicology dossiers where in vivo or validated in vitro data are mandated.
Applications
Repeated-dose skin irritation data are used throughout the cosmetic product lifecycle:
- Registration and filing of cosmetics and new cosmetic ingredients, including safety assessment dossiers under China's Cosmetics Supervision and Administration Regulation
- Market access documentation for regions requiring local toxicology summaries, including ASEAN member states and the Gulf region
- Research and development screening to compare formulation candidates and optimize surfactant or preservative systems
- Substantiation of marketing claims related to mildness, gentleness, and skin compatibility
- Post-market investigation of consumer complaints and adverse reaction reports
- Weight-of-evidence safety evaluations that combine in vitro data, in chemico data such as OECD TG 442 series sensitization screens, and existing literature
FAQ
What is the difference between skin irritation and skin sensitization?
Skin irritation is a localized, reversible inflammatory response caused by direct damage to skin cells and usually appears shortly after exposure. Sensitization is an immune-mediated delayed hypersensitivity that develops only after repeated induction and involves the adaptive immune system. Different tests are used for each endpoint: repeated-dose patch protocols address irritation, while methods such as the local lymph node assay (OECD TG 429) address sensitization.
When is a repeated-dose test required instead of an acute test?
Repeated-dose testing is generally indicated for products intended for daily or prolonged use, for leave-on formulations, for ingredients with borderline acute results, and when a regulatory dossier specifically requires cumulative irritation data, as in registration files prepared under the Safety and Technical Standards for Cosmetics (2015).
Is animal testing still required?
Requirements vary by market. The European Union prohibits animal testing for cosmetics. China has removed mandatory pre-market animal testing for many general, domestically manufactured cosmetics, while certain scenarios, such as some special-use products, new ingredients, and specific import situations, may still require it. Many sponsors now rely on validated in vitro methods and existing safety data assembled by accredited third-party laboratories.
How long does the study take?
A standard 14-day repeated-dose rabbit study, including acclimatization and post-exposure observation, typically requires four to six weeks from sample receipt to final report. In vitro RhE assays can often be completed within one to two weeks, although overall timelines depend on laboratory scheduling and protocol design.
What sample volume is needed and how should samples be submitted?
Most protocols require 30 to 50 g or mL of the final product, packaged in inert containers and shipped with a completed submission form identifying the product name, batch number, intended use concentration, and physical characteristics. Samples should be stable, representative of commercial production, and accompanied by appropriate safety handling information.